US20180321218A1 - Medical Toilet with Aptamer Sensors to Analyze Urine - Google Patents
Medical Toilet with Aptamer Sensors to Analyze Urine Download PDFInfo
- Publication number
- US20180321218A1 US20180321218A1 US15/589,403 US201715589403A US2018321218A1 US 20180321218 A1 US20180321218 A1 US 20180321218A1 US 201715589403 A US201715589403 A US 201715589403A US 2018321218 A1 US2018321218 A1 US 2018321218A1
- Authority
- US
- United States
- Prior art keywords
- urine
- aptamer
- medical toilet
- toilet
- aptamers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/007—Devices for taking samples of body liquids for taking urine samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
- A61B5/207—Sensing devices adapted to collect urine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6887—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient mounted on external non-worn devices, e.g. non-medical devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3276—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction being a hybridisation with immobilised receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48785—Electrical and electronic details of measuring devices for physical analysis of liquid biological material not specific to a particular test method, e.g. user interface or power supply
- G01N33/48792—Data management, e.g. communication with processing unit
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
- G01N2021/6419—Excitation at two or more wavelengths
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Definitions
- This disclosure relates to devices and methods for analyzing urine samples to assess health status and to aptamer technology.
- Laboratory tests including analysis of urine analytes, can be inconvenient and require a user to visit a healthcare facility.
- the collection process in a specimen cup or test strip on which a user may urinate directly may be unsanitary resulting in spilled or dripped urine.
- a convenient and simple device for collecting and analyzing urine is needed.
- a device which may be used in a user's home without the need to visit a healthcare facility is even more desirable.
- Aptamer technology has provided a wealth of mechanisms which may be used to detect drugs, proteins, and other analytes in biological fluids. It is desirable to adapt aptamer technology to make it available for in-home analysis of bodily fluids. Doing so would make aptamer technology available to more users in a convenient and discreet platform.
- a user may urinate normally into a toilet bowl.
- the urine may contact one or more aptamers within the medical toilet.
- the aptamers may include at least one binding site for one or more components of a user's urine.
- the aptamers may produce an electrochemical signal, a fluorescent signal, or a colorimetric signal.
- the medical toilet may include a detection device which may detect the signal produced by the bound aptamers.
- the medical toilet includes a urine capture reservoir and fluid handling system which may collect urine and direct it to a measurement cell.
- the medical toilet includes multiple aptamers which, together, may detect a plurality of components in a user's urine. Consequently, the medical toilet may screen a urine sample for a panel of urine analytes, proteins, drugs, or drug markers.
- the medical toilet includes a controller which may store data and which may include computer readable medium.
- the controller may collect data comprising signals produced by the aptamers and it may then analyze the signals. This may be particularly useful when assaying a urine sample using a panel of aptamers which detect different urine components.
- FIG. 1 is a cross-sectional view of an embodiment of the disclosed in-toilet urinalysis system delivering urine into a series of cuvettes.
- FIG. 2 is an aerial view of an embodiment of a toilet which includes the disclosed in-toilet urinalysis system.
- FIG. 3A is an embodiment of a portion of the in-toilet urinalysis system in which a solenoid moves the series of cuvettes past a capillary opening dispensing urine.
- FIG. 3B is an embodiment of a portion of the in-toilet urinalysis system in which a track and grip rollers move the series of cuvettes past the capillary opening.
- FIG. 4A illustrates an embodiment of an electrochemical aptamer sensor within a cuvette which may be included in the disclosed in-toilet urinalysis system.
- FIG. 4B illustrates an embodiment of an aptamer sensor within a cuvette which emits a fluorescent signal and which may be included in the disclosed in-toilet urinalysis system.
- FIG. 4C illustrates an embodiment of and aptamer sensor within a cuvette which produces a colorimetric signal and which may be included in the disclosed in-toilet urinalysis system.
- FIG. 5 is a channel within an embodiment of the disclosed in-toilet urinalysis system which includes an optical sensor detecting a fluorescent signal from an aptamer.
- Toilet as used herein, means a device that collects biological products of a mammal, including urine and feces.
- Medical toilet means a toilet that includes one or more medical devices and/or other analytical equipment which may be used to assess a user's health or diagnose disease.
- User means any mammal, human or animal, from which a urine sample is deposited into the in-toilet urinalysis system disclosed herein and analyzed.
- Nucleic acid as used herein, means deoxyribonucleic acid, ribonucleic acid, or analogs thereof. Nucleic acid, as used herein, may mean a single stranded or double stranded molecule.
- the in-toilet urinalysis system may include at least one aptamer sensor.
- the aptamer sensor may include at least one aptamer comprised of a nucleotide or peptide.
- the aptamer is on a stable protein scaffold.
- the aptamer may be in solution.
- the aptamer may emit a detectable signal which may be an electrochemical signal, a fluorescent signal, or a colorimetric signal.
- the aptamer may include aptamers and aptamer sensors as reviewed by Song, S., Wang, L., Li, J., Zhao, J., and Fan, C. (2008) Aptamer-based biosensors. Trends Analyt. Chem. 27, 108-117 which is hereby incorporated by reference in its entirety.
- the medical toilet may include an electrochemical cell.
- the electrochemical signal may be an electric current.
- the signal may be a change in a feature in a voltammetry curve.
- the change in a feature in a voltammetry curve may be a voltage shift or a change in a peak shape.
- the electrochemical cell may include a bias or voltammetry circuit.
- the bias or voltammetry circuit may be connected to a reference electrode.
- the electrochemical cell may include a counter electrode and a functionalized electrode.
- the functionalized electrode may comprise a noble metal.
- the functionalized electrode may comprise a surface comprising a noble metal selected from the group consisting of gold, ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, and combinations, mixtures, and alloys thereof.
- the functionalized electrode may be bound to at least one aptamer.
- the at least one aptamer may include one or more binding sites for one or more components of a user's urine.
- the medical toilet may include multiple aptamers, each with different binding sites which bind to a different component of a user's urine. Consequently, the medical toilet may detect a plurality of urine components nearly simultaneously. For example, a user's urine may be analyzed using specific urine analyte panel. Alternatively, the user's urine may be tested for an array of pharmaceuticals or drug tags.
- the aptamer may catalyze a chemical reaction when the component of the user's urine binds to the binding site. The chemical reaction may modify the component of the user's urine.
- the medical toilet may include a fluorescence spectrometer and at least one fluorescence cell.
- the medical toilet may include at least one aptamer, and each aptamer may include a binding site which binds a component of a user's urine.
- the fluorescence spectrometer may include an excitation light source, a urine sample flow path, and a fluorescence detector.
- the excitation light source may direct light toward the urine sample flow path.
- the fluorescence detector may receive non-specular light from the urine sample flow path.
- the aptamer includes both a fluorophore and a quencher.
- the fluorophore and quencher may be bound to the nucleotide or peptide of the aptamer.
- the nucleotide or peptide may undergo a conformational change. This conformational change may move the quencher further away from the fluorophore.
- the fluorophore may then emit a signal that the fluorescence detector may measure.
- the fluorescent aptamer may be in solution.
- the solution may be added to one or more fluorescence cells and mixed therein with a sample of a user's urine.
- the medical toilet may include a dispensing system which may deliver the aptamer solution into the one or more fluorescence cells.
- a controller may be connected to the dispensing system which may modulate which aptamer solution is dispensed into the one or more fluorescent cells.
- each of the fluorescent aptamers may include one or more binding sites for one or more components of a user's urine.
- the medical toilet may include multiple fluorescent aptamers, each with different binding sites which bind to a different component of a user's urine. Consequently, the medical toilet may detect a plurality of urine components nearly simultaneously. For example, a user's urine may be analyzed using specific urine analyte panel. Alternatively, the user's urine may be tested for an array of pharmaceuticals or drug tags.
- the medical toilet may include an absorption spectrometer and at least one absorption cell.
- the colorimetric aptamers may include one or more binding sites for one or more components of a user's urine.
- the medical toilet may include multiple colorimetric aptamers, each with different binding sites which bind to a different component of a user's urine. Consequently, the medical toilet may detect a plurality of urine components nearly simultaneously. For example, a user's urine may be analyzed using specific urine analyte panel. Alternatively, the user's urine may be tested for an array of pharmaceuticals or drug tags.
- the colorimetric aptamers may include a plurality of nanoparticles.
- the plurality of nanoparticles may be a first color when bound to the at least one aptamer.
- the plurality of nanoparticles may be a second color when aggregated to each other.
- the absorption spectrometer may measure the change in color which functions as a signal that the aptamers have bound to their target urine component.
- Embodiments of colorimetric aptamers include those reviewed by Song et al. (2008).
- the nanoparticles are gold nanoparticles.
- Other colorimetric aptamers may include nanoparticles of noble metals such as ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, and combinations, mixtures, and alloys thereof.
- the colorimetric aptamers may be in solution.
- the solution may be added to an absorption cell and mixed with a sample of a user's urine therein.
- the medical toilet may include a dispensing system which may deliver the aptamer solution into one or more absorption cells.
- a controller may be connected to the dispensing system which may modulate which aptamer solution is dispensed into the one or more absorption cells.
- the medical toilet may include a urine capture reservoir and a fluid handling system.
- the fluid handling system may include a channel which fluidly connects the urine capture reservoir to at least one electrochemical, fluorescent, or absorption cell.
- Some embodiments include a urine capture reservoir and capillary as disclosed in U.S. patent application Ser. No. 15/414,197 filed on Jan. 24, 2017 which is hereby incorporated by reference in its entirety. Other methods of capturing and handling urine are within the scope of this disclosure.
- the medical toilet disclosed herein may include a controller.
- the controller may be connected to the functionalized electrode, the fluorescence spectrometer, the absorption spectrometer, or any device which measures a signal produced upon binding of a user's urine component to an aptamer.
- the controller may include computer readable medium which analyzes the signals.
- the controller may store information about the library of aptamers and the computer readable medium may analyze the signals collected from the panel of aptamers.
- FIG. 1 illustrates an embodiment of a urine capture reservoir and capillary system which may be used to collect a urine sample for analysis by the aptamer sensor.
- FIG. 1 shows a cross sectional view of an embodiment of a toilet bowl within a medical toilet.
- FIG. 1 also includes a series of cuvettes which may be part of an aptamer sensor according to the disclosure.
- a first end 110 and a second end 120 of a urine capture reservoir are shown. In the embodiment of FIG. 1 , first end 110 is wider than second end 120 . The relative widths of first end 110 and second end 120 , as illustrated, may not be proportional.
- a channel is shown which includes two sections. First section 140 is open at both ends and defines orifice 130 .
- Orifice 130 leads into the urine capture reservoir within the toilet bowl and collects urine.
- Second section 150 of the channel is connected to first section 140 .
- First section 140 may include a noncompliant material which may be stainless steel, polyvinyl chloride (PVC) pipe, or other noncompliant polymer.
- Second section 150 may include a compliant material which may be compliant rubber.
- FIG. 1 The embodiment shown in FIG. 1 includes pinch valve 160 which is shown in its open state. When actuated, pinch valve 160 may compress section 150 thereby closing off the path of fluid through the orifice and into the channel. An open end of second section 150 is connected to capillary 170 . Capillary 170 includes distal opening 172 . A user's urine stream may be temporarily collected in the urine capture reservoir and enter orifice 130 . The urine may travel through first end 140 and second end 150 of the channel and into capillary 170 .
- a series of cuvettes is shown below distal opening 172 .
- the series of cuvettes include cuvettes 195 a - f .
- Cuvettes 195 a - f may be moved laterally along a track comprising track rails 180 a and 180 b .
- Track rail 180 a includes 190 a and 190 b while track rail 180 b includes grip rollers that are not visible from the view shown in FIG. 1 .
- each cuvette may be loaded with a urine sample which may be dispensed through distal opening 172 .
- FIG. 1 also includes slit-shaped opening 135 which may collect urine for other analysis techniques.
- FIG. 2 shows an aerial view of medical toilet 200 which is an embodiment of a medical toilet that includes the urine capture reservoir illustrated in FIG. 1 .
- Medical toilet 200 includes toilet bowl 210 and toilet seat 220 .
- a urine capture reservoir is shown within toilet bowl 210 which includes first end 110 .
- Orifice 130 is shown at first end 110 and slit-shaped opening 135 is shown at the second end of the urine capture reservoir which is narrower than first end 110 .
- FIG. 3A includes an embodiment of a device for loading urine into a series of cuvettes which includes a solenoid.
- a series of cuvettes as shown in FIG. 1 are loaded between track rails 180 a and 180 b .
- the series of cuvettes is positioned below capillary 170 .
- Solenoid 305 extends and applies force to push bar 310 .
- Push bar 310 then applies force to cuvette 195 a and pushes the series of cuvettes laterally past capillary 170 .
- solenoid 405 extends further, the series of cuvettes moves to the right on FIG.
- each of cuvettes 195 a - f are sequentially positioned directly below distal opening 172 and urine is dispensed into each of cuvettes 195 a - f .
- FIG. 3B illustrates another device which may be used to move the series of cuvettes shown in FIG. 1 .
- This device includes track rails 180 a and 180 b .
- Grip rollers 190 a and 190 b are shown connected to track rail 180 a .
- Another set of grip rollers may be positioned on the opposite side of the series of cuvettes and connected to track rail 180 b .
- a motor causes the grip rollers to rotate and move the series of cuvettes laterally.
- cuvettes 195 a - f (not all are labelled for purposes of clarity) are sequentially positioned below opening 172 of capillary 170 and receive a sample of urine for analysis by an aptamer sensor within each cuvette.
- FIG. 4A-C illustrate three types of aptamers which may be included in the disclosed medical toilet.
- FIG. 4A illustrates an electrochemical aptamer sensor which may be used as a component of the disclosed invention.
- Cuvette 410 may receive a sample of urine for analysis.
- Cuvette 410 includes an aptamer that includes electrode 410 which is connected to nucleic acid 430 .
- An electroactive ferrocene label 440 is attached to a terminus of nucleic acid 430 .
- Nucleic acid 430 includes a binding site for a target molecule which may be a component of a user's urine.
- nucleic acid 430 is relatively flexible and its length positions ferrocene label 440 far enough away from electrode 410 that ferrocene label 440 does not make contact with electrode 410 .
- nucleic acid 430 folds into a looped configuration when target molecule 450 binds to the binding site on nucleic acid 430 .
- This looped configuration places ferrocene label 440 near electrode 410 thus producing an electrochemical signal.
- FIG. 4B illustrates a fluorescent aptamer sensor which may be used as a component of the disclosed invention.
- the aptamer sensor in cuvette 410 includes single stranded nucleic acid 460 which includes a binding site for target molecule 450 and which is shown in a hairpin configuration.
- the 5 ′ and 3 ′ termini of single stranded nucleic acid 460 are complementary so that they hybridize to each other creating double stranded section 470 .
- Single stranded hairpin loop 465 is between the complementary 5 ′ and 3 ′ termini.
- One terminus of single stranded nucleic acid 460 is labeled with fluorophore 480 and the other terminus of single stranded nucleic acid 460 is labeled with quencher 490 .
- the configuration shown on the left side of FIG. 4B occurs in the absence of target molecule 450 . In this configuration, quencher 490 is near fluorophore 480 and quenches the fluorescent signal.
- target molecule 450 has bound its binding site within single stranded nucleic acid 460 causing double stranded region 470 to separate. Fluorophore 480 and quencher 490 are consequently separating such that quencher 490 no longer quenches the fluorescent signal of fluorophore 480 . A fluorimeter may then read a fluorescent signal emitted by the aptamer.
- FIG. 4C illustrates a colorimetric aptamer sensor which may be used as a component of the disclosed invention.
- the aptamer sensor in cuvette 410 includes aptamers 497 a - i which are single stranded nucleic acids and which each include a binding site for target molecule 450 .
- Aptamers 497 a - i are hybridized to short, complementary single stranded DNA strands which are bound to nanoparticles 495 a , 495 b , and 495 c .
- nanoparticles 495 a - c are gold and or other noble metal nanoparticles.
- nanoparticles 495 a - c are a first color, shown as black.
- FIG. 4C shows the colorimetric aptamer sensor in the presence of target molecule 450 .
- Target molecule 450 has bound its target site within aptamers 497 a - i (not all shown for clarity).
- aptamers 497 a - i change their structure.
- Nanoparticles 495 a - c and their associated short, complementary single stranded DNA strands dissociate from aptamers 497 a - i .
- Nanoparticles 495 a - c are unstable in the salt concentration of the urine solution and aggregate. The aggregation causes a color change, shown as white in FIG. 4C .
- the color change may be detected by an absorption spectrometer within the medical toilet.
- FIG. 5 illustrates a fluorescence spectrometer which may be within a medical toilet and which may detect a signal emitted by an aptamer that includes a fluorophore.
- Channel 540 includes optical windows 530 a and 530 b and may receive a urine sample.
- Light source 510 emits light including varied excitation wavelengths as shown by the three arrows pointing in different directions. The light passes through filter 520 which blocks all but one or a range of excitation wavelengths as shown by the single horizontal arrow. The light sequentially passes through optical window 530 a , the contents of channel 540 , and optical window 530 b . Light emitted from optical window 530 b is detected fluorimeter 550 .
- Aptamer 460 as presented in the right side of FIG. 4B is shown in channel 450 . Aptamer 460 is bound to target molecule 450 and emits a fluorescent signal which may be detected by fluorimeter 550 .
Abstract
Description
- This disclosure relates to devices and methods for analyzing urine samples to assess health status and to aptamer technology.
- Laboratory tests, including analysis of urine analytes, can be inconvenient and require a user to visit a healthcare facility. In the case or urinalysis, the collection process in a specimen cup or test strip on which a user may urinate directly may be unsanitary resulting in spilled or dripped urine. A convenient and simple device for collecting and analyzing urine is needed. A device which may be used in a user's home without the need to visit a healthcare facility is even more desirable.
- Aptamer technology has provided a wealth of mechanisms which may be used to detect drugs, proteins, and other analytes in biological fluids. It is desirable to adapt aptamer technology to make it available for in-home analysis of bodily fluids. Doing so would make aptamer technology available to more users in a convenient and discreet platform.
- We disclose an in-toilet urinalysis system which uses aptamer-mediated sensors to detect analytes in a user's urine. To use the disclosed system, a user may urinate normally into a toilet bowl. The urine may contact one or more aptamers within the medical toilet. The aptamers may include at least one binding site for one or more components of a user's urine. The aptamers may produce an electrochemical signal, a fluorescent signal, or a colorimetric signal. The medical toilet may include a detection device which may detect the signal produced by the bound aptamers.
- In some embodiments, the medical toilet includes a urine capture reservoir and fluid handling system which may collect urine and direct it to a measurement cell.
- In some embodiments, the medical toilet includes multiple aptamers which, together, may detect a plurality of components in a user's urine. Consequently, the medical toilet may screen a urine sample for a panel of urine analytes, proteins, drugs, or drug markers.
- In some embodiments, the medical toilet includes a controller which may store data and which may include computer readable medium. The controller may collect data comprising signals produced by the aptamers and it may then analyze the signals. This may be particularly useful when assaying a urine sample using a panel of aptamers which detect different urine components.
-
FIG. 1 is a cross-sectional view of an embodiment of the disclosed in-toilet urinalysis system delivering urine into a series of cuvettes. -
FIG. 2 is an aerial view of an embodiment of a toilet which includes the disclosed in-toilet urinalysis system. -
FIG. 3A is an embodiment of a portion of the in-toilet urinalysis system in which a solenoid moves the series of cuvettes past a capillary opening dispensing urine. -
FIG. 3B is an embodiment of a portion of the in-toilet urinalysis system in which a track and grip rollers move the series of cuvettes past the capillary opening. -
FIG. 4A illustrates an embodiment of an electrochemical aptamer sensor within a cuvette which may be included in the disclosed in-toilet urinalysis system. -
FIG. 4B illustrates an embodiment of an aptamer sensor within a cuvette which emits a fluorescent signal and which may be included in the disclosed in-toilet urinalysis system. -
FIG. 4C illustrates an embodiment of and aptamer sensor within a cuvette which produces a colorimetric signal and which may be included in the disclosed in-toilet urinalysis system. -
FIG. 5 is a channel within an embodiment of the disclosed in-toilet urinalysis system which includes an optical sensor detecting a fluorescent signal from an aptamer. - Toilet, as used herein, means a device that collects biological products of a mammal, including urine and feces.
- Medical toilet, as used herein, means a toilet that includes one or more medical devices and/or other analytical equipment which may be used to assess a user's health or diagnose disease.
- User, as used herein, means any mammal, human or animal, from which a urine sample is deposited into the in-toilet urinalysis system disclosed herein and analyzed.
- Nucleic acid, as used herein, means deoxyribonucleic acid, ribonucleic acid, or analogs thereof. Nucleic acid, as used herein, may mean a single stranded or double stranded molecule.
- While this invention is susceptible of embodiment in many different forms, there are shown in the drawings, which will herein be described in detail, several specific embodiments with the understanding that the present disclosure is to be considered as an exemplification of the principals of the invention and is not intended to limit the invention to the illustrated embodiments.
- We disclose a medical toilet which includes an in-toilet urinalysis system. The in-toilet urinalysis system may include at least one aptamer sensor. The aptamer sensor may include at least one aptamer comprised of a nucleotide or peptide. In some embodiments, the aptamer is on a stable protein scaffold. In some embodiments, the aptamer may be in solution. The aptamer may emit a detectable signal which may be an electrochemical signal, a fluorescent signal, or a colorimetric signal. The aptamer may include aptamers and aptamer sensors as reviewed by Song, S., Wang, L., Li, J., Zhao, J., and Fan, C. (2008) Aptamer-based biosensors. Trends Analyt. Chem. 27, 108-117 which is hereby incorporated by reference in its entirety.
- In embodiments in which the at least one aptamer emits an electrochemical signal, the medical toilet may include an electrochemical cell. The electrochemical signal may be an electric current. In some embodiments, the signal may be a change in a feature in a voltammetry curve. The change in a feature in a voltammetry curve may be a voltage shift or a change in a peak shape.
- The electrochemical cell may include a bias or voltammetry circuit. The bias or voltammetry circuit may be connected to a reference electrode. The electrochemical cell may include a counter electrode and a functionalized electrode. The functionalized electrode may comprise a noble metal. The functionalized electrode may comprise a surface comprising a noble metal selected from the group consisting of gold, ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, and combinations, mixtures, and alloys thereof.
- The functionalized electrode may be bound to at least one aptamer.
- The at least one aptamer may include one or more binding sites for one or more components of a user's urine. In some embodiments, the medical toilet may include multiple aptamers, each with different binding sites which bind to a different component of a user's urine. Consequently, the medical toilet may detect a plurality of urine components nearly simultaneously. For example, a user's urine may be analyzed using specific urine analyte panel. Alternatively, the user's urine may be tested for an array of pharmaceuticals or drug tags. In some embodiments, the aptamer may catalyze a chemical reaction when the component of the user's urine binds to the binding site. The chemical reaction may modify the component of the user's urine.
- In embodiments in which the at least one aptamer emits a fluorescent signal, the medical toilet may include a fluorescence spectrometer and at least one fluorescence cell. The medical toilet may include at least one aptamer, and each aptamer may include a binding site which binds a component of a user's urine.
- The fluorescence spectrometer may include an excitation light source, a urine sample flow path, and a fluorescence detector. The excitation light source may direct light toward the urine sample flow path. The fluorescence detector may receive non-specular light from the urine sample flow path.
- In some embodiments, the aptamer includes both a fluorophore and a quencher. The fluorophore and quencher may be bound to the nucleotide or peptide of the aptamer. When the component of the user's urine binds the binding site in the aptamer, the nucleotide or peptide may undergo a conformational change. This conformational change may move the quencher further away from the fluorophore. The fluorophore may then emit a signal that the fluorescence detector may measure.
- In some embodiments, the fluorescent aptamer may be in solution. The solution may be added to one or more fluorescence cells and mixed therein with a sample of a user's urine. The medical toilet may include a dispensing system which may deliver the aptamer solution into the one or more fluorescence cells. A controller may be connected to the dispensing system which may modulate which aptamer solution is dispensed into the one or more fluorescent cells.
- Similar to the electrochemical aptamers described above, each of the fluorescent aptamers may include one or more binding sites for one or more components of a user's urine. The medical toilet may include multiple fluorescent aptamers, each with different binding sites which bind to a different component of a user's urine. Consequently, the medical toilet may detect a plurality of urine components nearly simultaneously. For example, a user's urine may be analyzed using specific urine analyte panel. Alternatively, the user's urine may be tested for an array of pharmaceuticals or drug tags.
- In embodiments in which the at least one aptamer produces a colorimetric signal, the medical toilet may include an absorption spectrometer and at least one absorption cell. As with the electrochemical and fluorescent aptamers, the colorimetric aptamers may include one or more binding sites for one or more components of a user's urine. In some embodiments, the medical toilet may include multiple colorimetric aptamers, each with different binding sites which bind to a different component of a user's urine. Consequently, the medical toilet may detect a plurality of urine components nearly simultaneously. For example, a user's urine may be analyzed using specific urine analyte panel. Alternatively, the user's urine may be tested for an array of pharmaceuticals or drug tags.
- The colorimetric aptamers may include a plurality of nanoparticles. The plurality of nanoparticles may be a first color when bound to the at least one aptamer. In contrast, the plurality of nanoparticles may be a second color when aggregated to each other. The absorption spectrometer may measure the change in color which functions as a signal that the aptamers have bound to their target urine component. Embodiments of colorimetric aptamers include those reviewed by Song et al. (2008). In an example, the nanoparticles are gold nanoparticles. Other colorimetric aptamers may include nanoparticles of noble metals such as ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, and combinations, mixtures, and alloys thereof.
- Similar to the fluorescent aptamers, the colorimetric aptamers may be in solution. The solution may be added to an absorption cell and mixed with a sample of a user's urine therein. The medical toilet may include a dispensing system which may deliver the aptamer solution into one or more absorption cells. A controller may be connected to the dispensing system which may modulate which aptamer solution is dispensed into the one or more absorption cells.
- In any of the embodiments described above, the medical toilet may include a urine capture reservoir and a fluid handling system. The fluid handling system may include a channel which fluidly connects the urine capture reservoir to at least one electrochemical, fluorescent, or absorption cell. Some embodiments include a urine capture reservoir and capillary as disclosed in U.S. patent application Ser. No. 15/414,197 filed on Jan. 24, 2017 which is hereby incorporated by reference in its entirety. Other methods of capturing and handling urine are within the scope of this disclosure.
- The medical toilet disclosed herein may include a controller. The controller may be connected to the functionalized electrode, the fluorescence spectrometer, the absorption spectrometer, or any device which measures a signal produced upon binding of a user's urine component to an aptamer. The controller may include computer readable medium which analyzes the signals. In embodiments in which the medical toilet includes multiple aptamers which detect a panel of components of a user's urine, the controller may store information about the library of aptamers and the computer readable medium may analyze the signals collected from the panel of aptamers.
- Referring now to the drawings,
FIG. 1 illustrates an embodiment of a urine capture reservoir and capillary system which may be used to collect a urine sample for analysis by the aptamer sensor.FIG. 1 shows a cross sectional view of an embodiment of a toilet bowl within a medical toilet.FIG. 1 also includes a series of cuvettes which may be part of an aptamer sensor according to the disclosure. Afirst end 110 and asecond end 120 of a urine capture reservoir are shown. In the embodiment ofFIG. 1 ,first end 110 is wider thansecond end 120. The relative widths offirst end 110 andsecond end 120, as illustrated, may not be proportional. A channel is shown which includes two sections.First section 140 is open at both ends and definesorifice 130.Orifice 130 leads into the urine capture reservoir within the toilet bowl and collects urine.Second section 150 of the channel is connected tofirst section 140.First section 140 may include a noncompliant material which may be stainless steel, polyvinyl chloride (PVC) pipe, or other noncompliant polymer.Second section 150 may include a compliant material which may be compliant rubber. - The embodiment shown in
FIG. 1 includespinch valve 160 which is shown in its open state. When actuated,pinch valve 160 may compresssection 150 thereby closing off the path of fluid through the orifice and into the channel. An open end ofsecond section 150 is connected tocapillary 170.Capillary 170 includesdistal opening 172. A user's urine stream may be temporarily collected in the urine capture reservoir and enterorifice 130. The urine may travel throughfirst end 140 andsecond end 150 of the channel and intocapillary 170. - A series of cuvettes is shown below
distal opening 172. The series of cuvettes include cuvettes 195 a-f. Cuvettes 195 a-f may be moved laterally along a track comprising track rails 180 a and 180 b.Track rail 180 a includes 190 a and 190 b whiletrack rail 180 b includes grip rollers that are not visible from the view shown inFIG. 1 . As the track moves cuvettes 195 a-f laterally, each cuvette may be loaded with a urine sample which may be dispensed throughdistal opening 172.FIG. 1 also includes slit-shapedopening 135 which may collect urine for other analysis techniques. -
FIG. 2 shows an aerial view ofmedical toilet 200 which is an embodiment of a medical toilet that includes the urine capture reservoir illustrated inFIG. 1 .Medical toilet 200 includestoilet bowl 210 andtoilet seat 220. A urine capture reservoir is shown withintoilet bowl 210 which includesfirst end 110.Orifice 130 is shown atfirst end 110 and slit-shapedopening 135 is shown at the second end of the urine capture reservoir which is narrower thanfirst end 110. -
FIG. 3A includes an embodiment of a device for loading urine into a series of cuvettes which includes a solenoid. A series of cuvettes as shown inFIG. 1 are loaded betweentrack rails capillary 170.Solenoid 305 extends and applies force to pushbar 310.Push bar 310 then applies force to cuvette 195 a and pushes the series of cuvettes laterally pastcapillary 170. As solenoid 405 extends further, the series of cuvettes moves to the right onFIG. 3A so that each of cuvettes 195 a-f are sequentially positioned directly belowdistal opening 172 and urine is dispensed into each of cuvettes 195 a-f. Note that, for purposes of clarity, not all cuvettes are labeled inFIGS. 3A and 3B . -
FIG. 3B illustrates another device which may be used to move the series of cuvettes shown inFIG. 1 . This device includes track rails 180 a and 180 b.Grip rollers rail 180 a. Another set of grip rollers may be positioned on the opposite side of the series of cuvettes and connected to trackrail 180 b. A motor causes the grip rollers to rotate and move the series of cuvettes laterally. As illustrated inFIG. 3B , cuvettes 195 a-f (not all are labelled for purposes of clarity) are sequentially positioned below opening 172 ofcapillary 170 and receive a sample of urine for analysis by an aptamer sensor within each cuvette. -
FIG. 4A-C illustrate three types of aptamers which may be included in the disclosed medical toilet.FIG. 4A illustrates an electrochemical aptamer sensor which may be used as a component of the disclosed invention.Cuvette 410 may receive a sample of urine for analysis.Cuvette 410 includes an aptamer that includeselectrode 410 which is connected tonucleic acid 430. Anelectroactive ferrocene label 440 is attached to a terminus ofnucleic acid 430.Nucleic acid 430 includes a binding site for a target molecule which may be a component of a user's urine. - As illustrated on the left of
FIG. 4A , in the absence oftarget molecule 450,nucleic acid 430 is relatively flexible and its length positionsferrocene label 440 far enough away fromelectrode 410 thatferrocene label 440 does not make contact withelectrode 410. - As illustrated on the right side of
FIG. 4A ,nucleic acid 430 folds into a looped configuration whentarget molecule 450 binds to the binding site onnucleic acid 430. This looped configuration placesferrocene label 440 nearelectrode 410 thus producing an electrochemical signal. -
FIG. 4B illustrates a fluorescent aptamer sensor which may be used as a component of the disclosed invention. The aptamer sensor incuvette 410 includes single strandednucleic acid 460 which includes a binding site fortarget molecule 450 and which is shown in a hairpin configuration. The 5′ and 3′ termini of single strandednucleic acid 460 are complementary so that they hybridize to each other creating double strandedsection 470. Single strandedhairpin loop 465 is between the complementary 5′ and 3′ termini. One terminus of single strandednucleic acid 460 is labeled withfluorophore 480 and the other terminus of single strandednucleic acid 460 is labeled withquencher 490. The configuration shown on the left side ofFIG. 4B occurs in the absence oftarget molecule 450. In this configuration, quencher 490 is nearfluorophore 480 and quenches the fluorescent signal. - As shown in the right side of
FIG. 4B ,target molecule 450 has bound its binding site within single strandednucleic acid 460 causing double strandedregion 470 to separate.Fluorophore 480 andquencher 490 are consequently separating such thatquencher 490 no longer quenches the fluorescent signal offluorophore 480. A fluorimeter may then read a fluorescent signal emitted by the aptamer. -
FIG. 4C illustrates a colorimetric aptamer sensor which may be used as a component of the disclosed invention. The aptamer sensor incuvette 410 includes aptamers 497 a-i which are single stranded nucleic acids and which each include a binding site fortarget molecule 450. Aptamers 497 a-i are hybridized to short, complementary single stranded DNA strands which are bound tonanoparticles FIG. 4C , nanoparticles 495 a-c are a first color, shown as black. - The right side of
FIG. 4C shows the colorimetric aptamer sensor in the presence oftarget molecule 450.Target molecule 450 has bound its target site within aptamers 497 a-i (not all shown for clarity). Upon binding totarget molecule 450, aptamers 497 a-i change their structure. Nanoparticles 495 a-c and their associated short, complementary single stranded DNA strands dissociate from aptamers 497 a-i. Nanoparticles 495 a-c are unstable in the salt concentration of the urine solution and aggregate. The aggregation causes a color change, shown as white inFIG. 4C . The color change may be detected by an absorption spectrometer within the medical toilet. -
FIG. 5 illustrates a fluorescence spectrometer which may be within a medical toilet and which may detect a signal emitted by an aptamer that includes a fluorophore.Channel 540 includesoptical windows Light source 510 emits light including varied excitation wavelengths as shown by the three arrows pointing in different directions. The light passes throughfilter 520 which blocks all but one or a range of excitation wavelengths as shown by the single horizontal arrow. The light sequentially passes throughoptical window 530 a, the contents ofchannel 540, andoptical window 530 b. Light emitted fromoptical window 530 b is detectedfluorimeter 550.Aptamer 460 as presented in the right side ofFIG. 4B is shown inchannel 450.Aptamer 460 is bound to targetmolecule 450 and emits a fluorescent signal which may be detected byfluorimeter 550. - While specific embodiments have been illustrated and described above, it is to be understood that the disclosure provided is not limited to the precise configuration, steps, and components disclosed. Various modifications, changes, and variations apparent to those of skill in the art may be made in the arrangement, operation, and details of the methods and systems disclosed, with the aid of the present disclosure.
- Without further elaboration, it is believed that one skilled in the art can use the preceding description to utilize the present disclosure to its fullest extent. The examples and embodiments disclosed herein are to be construed as merely illustrative and exemplary and not a limitation of the scope of the present disclosure in any way. It will be apparent to those having skill in the art that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the disclosure herein.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/589,403 US20180321218A1 (en) | 2017-05-08 | 2017-05-08 | Medical Toilet with Aptamer Sensors to Analyze Urine |
US16/904,315 US11635424B2 (en) | 2017-05-08 | 2020-06-17 | Medical toilet with aptamer sensors to analyze urine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/589,403 US20180321218A1 (en) | 2017-05-08 | 2017-05-08 | Medical Toilet with Aptamer Sensors to Analyze Urine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/904,315 Division US11635424B2 (en) | 2017-05-08 | 2020-06-17 | Medical toilet with aptamer sensors to analyze urine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180321218A1 true US20180321218A1 (en) | 2018-11-08 |
Family
ID=64014682
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/589,403 Abandoned US20180321218A1 (en) | 2017-05-08 | 2017-05-08 | Medical Toilet with Aptamer Sensors to Analyze Urine |
US16/904,315 Active 2037-12-30 US11635424B2 (en) | 2017-05-08 | 2020-06-17 | Medical toilet with aptamer sensors to analyze urine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/904,315 Active 2037-12-30 US11635424B2 (en) | 2017-05-08 | 2020-06-17 | Medical toilet with aptamer sensors to analyze urine |
Country Status (1)
Country | Link |
---|---|
US (2) | US20180321218A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020530568A (en) * | 2017-08-11 | 2020-10-22 | ダブリュケー ホールディングス,インコーポレイティド | Biomaterial collector and assembly |
US20220018799A1 (en) * | 2018-11-19 | 2022-01-20 | Zio Health Ltd. | System and methods for measuring analyte concentration |
EP4118424A4 (en) * | 2020-03-10 | 2024-04-17 | Prajakta Kulkarni | Devices and methods of urinalysis for real-time monitoring of organ health |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020085959A1 (en) * | 1991-03-04 | 2002-07-04 | Glen Carey | Cuvette for an automated analyzer |
US20120105837A1 (en) * | 2010-11-03 | 2012-05-03 | Pocared Diagnostics Ltd. | Optical Cup |
US20120308437A1 (en) * | 2009-12-14 | 2012-12-06 | Xiaoqun Zhou | Detector Module, a Method for Controlling the Detector Module and a Detection System |
US20150359522A1 (en) * | 2014-06-17 | 2015-12-17 | Palo Alto Research Center Incorporated | Point of care urine tester and method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3422125B2 (en) * | 1995-03-22 | 2003-06-30 | 東陶機器株式会社 | Urine analyzer with urine collection container with temperature sensing element |
-
2017
- 2017-05-08 US US15/589,403 patent/US20180321218A1/en not_active Abandoned
-
2020
- 2020-06-17 US US16/904,315 patent/US11635424B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020085959A1 (en) * | 1991-03-04 | 2002-07-04 | Glen Carey | Cuvette for an automated analyzer |
US20120308437A1 (en) * | 2009-12-14 | 2012-12-06 | Xiaoqun Zhou | Detector Module, a Method for Controlling the Detector Module and a Detection System |
US20120105837A1 (en) * | 2010-11-03 | 2012-05-03 | Pocared Diagnostics Ltd. | Optical Cup |
US20150359522A1 (en) * | 2014-06-17 | 2015-12-17 | Palo Alto Research Center Incorporated | Point of care urine tester and method |
Non-Patent Citations (1)
Title |
---|
S. Song Aptamer-based biosensors, Trends in Analytical Chemistry, 27(2), p. 108-117, Feb. 2008; hereinafter, Song * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020530568A (en) * | 2017-08-11 | 2020-10-22 | ダブリュケー ホールディングス,インコーポレイティド | Biomaterial collector and assembly |
US11317898B2 (en) * | 2017-08-11 | 2022-05-03 | Wk Holdings Inc. | Biomaterial collection method |
JP7237930B2 (en) | 2017-08-11 | 2023-03-13 | ダブリュケー ホールディングス,インコーポレイティド | Biological material collection device and assembly |
US20220018799A1 (en) * | 2018-11-19 | 2022-01-20 | Zio Health Ltd. | System and methods for measuring analyte concentration |
EP4118424A4 (en) * | 2020-03-10 | 2024-04-17 | Prajakta Kulkarni | Devices and methods of urinalysis for real-time monitoring of organ health |
Also Published As
Publication number | Publication date |
---|---|
US20200319159A1 (en) | 2020-10-08 |
US11635424B2 (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11635424B2 (en) | Medical toilet with aptamer sensors to analyze urine | |
EP3296718B1 (en) | Station for use with a test apparatus having integrated reaction and detection means | |
US9835620B2 (en) | Multiple-analyte assay device and system | |
Luong et al. | Biosensor technology: technology push versus market pull | |
CN101713772B (en) | Sensor for detecting analyte | |
US20200124625A1 (en) | Systems and methods for detecting a target analyte in a breath sample | |
CN110133277A (en) | Multi-scale analysis quality testing is fixed | |
US8349616B2 (en) | Assays | |
JP2011516889A5 (en) | ||
US20180180612A1 (en) | Monocyte integrin based microfluidic assay for evaluating coronary diseases | |
US20190070604A1 (en) | Systems and apparatus for detecting compounds in human biological samples | |
US20190176149A1 (en) | Field Portable, Handheld, Recirculating Surface Acoustic Wave and Method for Operating the Same | |
WO2021099677A1 (en) | Device and method for detecting of brain injury in a subject | |
Brunauer et al. | Integrated paper-based sensing devices for diagnostic applications | |
US11881313B2 (en) | Customized questions for user of analytical toilet | |
Younis et al. | Smartphone‐Based Biosensors | |
US20210278358A1 (en) | Methods for Detecting Analytes in Excreta in an Analytical Toilet | |
KR101663600B1 (en) | Cartridge for measuring glycohemoglobin in blood based on aptamer | |
CN202101997U (en) | Detecting device for quick diagnosis of acute myocardial infarction | |
Yamaguchi et al. | Salivary sensors for quantification of stress response biomarker | |
US20130029318A1 (en) | Microchips and Methods for Testing a Fluid Sample | |
US20240125763A1 (en) | Device to predict type 2 diabetes | |
CN105874320B (en) | Gas emptying system for nano-fluid biosensor | |
Simonet et al. | Analytical chemistry in modern society: what we can expect | |
US20230341422A1 (en) | A Home Test for Measuring Glucose Control and Kidney Function in Patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HALL, DAVID R;REEL/FRAME:046832/0478 Effective date: 20180811 Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOX, JOE;REEL/FRAME:046832/0440 Effective date: 20180811 Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PEARMAN, TERRECE;REEL/FRAME:046834/0374 Effective date: 20180811 |
|
AS | Assignment |
Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLEN, DAN;REEL/FRAME:046897/0127 Effective date: 20180811 Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HENDRICKS, DANIEL;REEL/FRAME:046897/0264 Effective date: 20180820 |
|
AS | Assignment |
Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROSENBROCK, CONRAD;REEL/FRAME:047058/0308 Effective date: 20181003 |
|
AS | Assignment |
Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NGUYEN, ANDREW;REEL/FRAME:047255/0648 Effective date: 20181022 |
|
AS | Assignment |
Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NIEDERHAUSER, TRAVIS;REEL/FRAME:049126/0209 Effective date: 20190509 |
|
AS | Assignment |
Owner name: HALL LABS LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BUTALA, STEVEN;REEL/FRAME:049170/0453 Effective date: 20190510 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
AS | Assignment |
Owner name: MEDIC, INC., UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HALL LABS LLC;REEL/FRAME:052671/0795 Effective date: 20200407 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |